Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 21,056 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ONE Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Preventing Early-Onset Colorectal Cancer in the VA

NCT07071454
View directory record Official record
Conditions
Colorectal Neoplasms, Mass Screening
Interventions
Patient intervention, PCP intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 49 Years
Enrollment
536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

NCT03897205
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Imlifidase, Plasma Exchange
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Nov 13, 2026, 9:05 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

The Pittsburgh Study Early Childhood

NCT05444205
View directory record Official record
Conditions
Child Development, Child Language, Child Behavior Problem, Parenting, Parent Child Abuse
Interventions
Text4Baby or Bright by Text Referral, Nurture Program Warm Referral, Video Interaction Project, Family Check-UP, Smart Beginnings, Healthy Families America Warm Referral, Family Center Warm Referral
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 6 Years
Enrollment
2,546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 1 Interventional Results available

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

NCT03803605
View directory record Official record
Conditions
HIV-1 Infection
Interventions
VRC07-523LS, Vorinostat (VOR)
Biological · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 2 Interventional Results available

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

NCT01657682
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
Interventions
Crenolanib besylate
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Nov 13, 2026, 9:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multi-ingredient Supplement for Strength and Power

NCT01971723
View directory record Official record
Conditions
Supplement
Interventions
T+ Supplement, Placebo
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Nov 13, 2026, 9:05 AM EST
Completed No phase listed Observational

Prospective Multicenter Trial to Compare Preformed vs Non Preformed Orbital Implants

NCT01121159
View directory record Official record
Conditions
Orbital Floor Fracture, Medial Orbital Wall Fracture
Interventions
orbital fracture repair
Procedure
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Nov 13, 2026, 9:05 AM EST
Recruiting Not applicable Interventional

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

NCT06526988
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Walnut Creek, California • Aurora, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 13, 2026, 9:05 AM EST
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 3 Interventional Results available

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

NCT02707861
View directory record Official record
Conditions
HIV
Interventions
ibalizumab, Optimized Background Regimen
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 1 Interventional

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

NCT03533673
View directory record Official record
Conditions
Pompe Disease
Interventions
ACTUS-101
Genetic
Lead sponsor
AskBio Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

NCT05219669
View directory record Official record
Conditions
Opioid Overdose
Interventions
Nalmefene Hydrochloride
Drug
Lead sponsor
Opiant Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Nov 13, 2026, 9:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Active You: A Novel Exercise Program for African Americans

NCT04280783
View directory record Official record
Conditions
Cardiovascular Risk Factor, Prediabetes, Overweight and Obesity, Sedentary Behavior
Interventions
The Physical Activity for The Heart (PATH) intervention, Be Active Your Way Booklet
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Beaver Falls, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 13, 2026, 9:05 AM EST
Completed Not applicable Interventional

Patient Adherence to Acupuncture Treatment

NCT03645083
View directory record Official record
Conditions
Adherence, Patient
Interventions
Telephone call, Text message
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

NCT00873041
View directory record Official record
Conditions
Non-transfusion Dependent Thalassemia
Interventions
deferasirox, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Nov 13, 2026, 9:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

SkinTE™ in the Treatment of Diabetic Foot Wounds

NCT03881254
View directory record Official record
Conditions
Diabetic Foot, Diabetic Foot Ulcer, Ulcer Foot
Interventions
Human Autologous Homologous Skin Construct, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing
Other
Lead sponsor
PolarityTE
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Martinsville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Nov 13, 2026, 9:05 AM EST
Suspended Phase 1 Interventional

Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

NCT00673829
View directory record Official record
Conditions
Breast Cancer
Interventions
Gene Modified T Cells, Gene Modified T Cells and Interleukin 2
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Nov 13, 2026, 9:05 AM EST
Completed Not applicable Interventional

Project Phoenix: Pilot Intervention for Smokers Who Are Not Ready to Quit Smoking

NCT03405129
View directory record Official record
Conditions
Smoking Cessation, Motivation
Interventions
Phoenix, NRT order button, Factoid
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Nov 13, 2026, 9:05 AM EST
Completed Not applicable Interventional

Educational Program for Various Health Literacy Levels to Improve the Health of Individuals With Heart Failure

NCT00378950
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Teach to Goal (TTG), Brief Educational Intervention (BEI)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 1 Interventional

Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil

NCT01219023
View directory record Official record
Conditions
Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
Interventions
sildenafil citrate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Nov 13, 2026, 9:05 AM EST
Terminated Phase 2 Interventional Results available

X-82 to Treat Age-related Macular Degeneration

NCT02348359
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
Interventions
X-82, Anti-VEGF, Placebo
Drug
Lead sponsor
Tyrogenex
Industry
Eligibility
50 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Nov 13, 2026, 9:05 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

High Level Pulsed Heat Versus Low Level Steady Heat in Subjects With Chronic Low Back Pain

NCT04109703
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Heat, Analgesia
Interventions
High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc., Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.
Device
Lead sponsor
Soovu Labs Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Nov 13, 2026, 9:05 AM EST
Completed Not applicable Interventional Results available

TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study

NCT01198470
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
TRIUMPH® Lumbar Artificial Disc
Device
Lead sponsor
Globus Medical Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Nov 13, 2026, 9:05 AM EST
Completed Phase 1 Interventional

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

NCT03467373
View directory record Official record
Conditions
B-Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Nov 13, 2026, 9:05 AM EST